Is There Really a Pill That Helps Dogs Live Longer? Where Loyal's Drugs Stand

No, there is no approved pill that makes dogs live longer, at least not yet. As of November 2026, the company Loyal has three lifespan drugs in development and has cleared real regulatory milestones with the FDA, but none of them is approved or for sale, and no study has yet shown how much longer treated dogs live. The one closest to market, LOY-002, is for senior dogs of nearly any size, not just big dogs.

The headlines have been confusing, and some got it wrong: a Mexican outlet ran “FDA avala pastilla antienvejecimiento” in late 2025, although its own article described only a preliminary step. So here is where things stand, drug by drug, using the FDA’s own explanation of the process and what Loyal has published.

The three drugs, in plain words

Drug	Meant for	Form	Status (Nov 2026)
LOY-002	Dogs 10+ years, at least 14 lb (6.35 kg)	Daily flavored chewable	FDA accepted the effectiveness expectation (Feb 2025) and the safety data (announced Jan 13, 2026). Manufacturing still open; Loyal expects to finish in 2027.
LOY-001	Large dogs, 7+ years, at least 40 lb (18 kg)	Vet-given injection every 3 to 6 months	Effectiveness expectation accepted in 2023. Early-stage; safety data being gathered.
LOY-003	Large dogs, 5+ years, at least 60 lb (27 kg), per Loyal’s current vet brief	Daily pill	Effectiveness expectation accepted (announced Sep 16, 2026). Early-stage; safety data being gathered.

Loyal describes LOY-002 as a “caloric-restriction mimetic,” a drug meant to give some of the benefits of eating less without the diet. Its active ingredient is confidential. LOY-003 is designed to lower growth hormone and IGF-1, and both big-dog drugs would be given only to adult dogs, so they would not change how big a puppy grows.

What the FDA has actually accepted

The FDA’s step for these drugs is called a “reasonable expectation of effectiveness.” It is the effectiveness bar for conditional approval. It is a lower bar than the “substantial evidence” needed for full approval, but the FDA’s safety and manufacturing standards are the same either way.

For LOY-002, two of the three big pieces are done: the effectiveness expectation (February 2025) and target animal safety. Loyal’s brief for veterinarians says the safety package included a standard study at one, three and five times the intended dose, with “no clinically significant adverse events observed at these doses,” plus field data from more than 400 pet dogs, some given the drug for up to a year. No table of side effects has been published.

The third piece, manufacturing, is still in progress. In January 2026 Loyal said it expects to complete it and apply for conditional approval in 2027. Its timeline has slipped before: in early 2025 it hoped to finish by the end of that year. Loyal’s own homepage says plainly that FDA approval is not guaranteed.

If conditional approval does come, the FDA rules are strict. The label must say the drug is conditionally approved pending full proof of effectiveness, the approval lasts a year at a time (renewable up to four times), and vets may not prescribe it outside the labeled group of dogs.

What has not been shown

How long, if at all, the drugs extend life. Loyal’s main trial, called STAY, is double-blinded and placebo-controlled: 1,300 dogs at about 70 clinics, each getting a daily chewable that is either LOY-002 or a placebo. It finished enrolling in July 2025, is designed to detect at least a one-year difference, and is expected to run about four years. Until it ends, nobody, including the owners, knows which dogs got the drug.

Loyal’s director of veterinary medicine put it honestly in an April 2026 interview with Fortune: “I don’t think there’s any way we can say you’re going to get X number of years or months more with your dog.” The company’s CEO has said she hopes for about a year, according to NBC News as reported by the Deseret News. That is a hope, not a result.

And the “almost two years longer” figure you may have seen? It comes from a classic study of Labrador Retrievers in which the dogs fed less lived almost two years longer on average than dogs fed to a normal body condition (Lawler and colleagues, 2008, as cited in Loyal’s own brief). That was a feeding study. No pill was involved.

Meanwhile, at the Dog Aging Project

The Dog Aging Project, a large U.S. study of aging in dogs, published two notable findings in the past year, and neither is a product:

• Dogs and people age in similar ways. In a 2026 paper in the Journal of Gerontology, researchers measured blood metabolites in 937 dogs and found that the ones linked to dying sooner in dogs closely matched those linked to dying sooner in people. Kate Creevy of Texas A&M cautions that “those biomarkers do not necessarily cause an outcome”: it is a starting point, not a blood test you can order.
• A rapamycin trial is underway. TRIAD is testing whether the drug rapamycin extends lifespan and healthspan in healthy middle-aged dogs. It is randomized and placebo-controlled, and it has reported no results yet.

What you can do now

The most reliable lever in all of this is still the one from the Labrador study: body condition. Ask your vet what your dog’s ideal weight is, learn to score body condition (a visible waist, ribs you can feel without pressing), and adjust portions as your dog ages and slows down. The free body condition score chart and weight tracker make that easy to keep up, and the feeding calculator gives you a starting portion to discuss with your vet.

For older dogs, regular checkups catch the slow changes that matter most. My guide to caring for a senior dog covers what changes with age, and the free senior dog wellness tracker helps you notice trends between visits. If a pill does arrive, it will be your vet who decides whether your dog fits the label. Until then, be wary of anything sold online with Loyal’s drug names on it.